Program Description
The use of immune checkpoint inhibitors (ICIs) has been well established in metastatic disease, leading to their investigation for use in earlier stages of cancer. Currently, few ICIs are approved for neoadjuvant and adjuvant indications, though clinical trials are underway in melanoma, non−small cell lung cancer, renal cell carcinoma, and other malignancies. In this multidisciplinary panel discussion, experts will review efficacy and safety data supporting the role of ICIs in early-stage cancers and strategies to overcome challenges associated with their therapeutic uptake. The panelists will explore patient populations likely to benefit from early initiation of ICIs in therapy, considerations for initiation and duration of therapy, as well as criteria to determine benefit for patients. The pharmacist’s role and considerations for management of immune-related adverse effects for patients receiving ICIs in the adjuvant setting compared with the metastatic setting will also be discussed.
Target audience: Oncology pharmacists, nurses, and physicians
Type of activity: Application
Release date: July 29, 2022
Expiration date: July 29, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the current and emerging uses of immune checkpoint inhibitors (ICIs) in early stages of cancer and supportive clinical data
- Compare challenges in integrating ICIs into early-stage cancers among oncologists, oncology nurses, and oncology pharmacists
- Explain the importance of prompt immune-related adverse effect (irAE) identification in early-stage cancers
- Develop a plan to monitor and manage irAEs that incorporates collaboration among oncologists, nurses, and pharmacists on the multidisciplinary cancer care team
Jessica Michaud Davis, PharmD, BCOP, CPP
Moderator
Clinical Pharmacist Coordinator
Adult Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
Robert L. Ferris, MD, PhD
Faculty Panelist
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Professor of Otolaryngology, Immunology, and Radiation Oncology
Pittsburgh, Pennsylvania
Kristi K Orbaugh, MSN, NP, AOCNP
Faculty Panelist
Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-368-H01-P. The activity is available for CE credit through July 29, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
ACCME credit:
https://www.gotoper.com/optimizing-immune-checkpoint-inhibitors-per
Disclosures
Faculty Panelists
Kristi K Orbaugh, MSN, NP, AOCNP, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: Eli Lilly, BMS, Coherus, Sanofi, Regeneron, MorphoSys, CTI, Gilead, DSI, AstraZeneca, Pfizer
Robert L. Ferris, MD, PhD, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Adagene, Aduro Biotech, Inc, Bicara Therapeutics, Brooklyn lmmunoTherapeutics, F. Hoffmann-La Roche Ltd, Everest Clinical Research Corp, Genocea Biosciences Inc, Kawa Research Institute, Inc, Mirati Therapeutics, Inc, Nanobiotix, Novasenta, PPD Development, LP, Sanofi, Zymeworks, Inc, Catenion
Advisory Board: Merck, Numab Therapeutics AG, OncoCyte, Pfizer, Rakuten Medical, Inc, Seagen, SIRPant lmmunotherapeutics, Vir Biotechnology, Bristol Myers Squibb, Hookipa Biotech GmbH, Coherus BioSciences, Instil Bio, MacroGenics, Lifescience Dynamics Ltd
Research Funding: AstraZeneca/Medlmmune, Bristol Myers Squibb, Novasenta, Tesaro
Stock: Novasenta
Other (clinical trial): AstraZeneca/Medlmmune, Bristol Myers Squibb, Merck
Other (data safety monitoring board): Mirror Biologics, Inc
Moderator
Jessica Michaud Davis, PharmD, BCOP, CPP, has the following relevant financial relationships with commercial interests to disclose:
Advisory Board: Regeneron/Sanofi
Speakers Bureau Exelixis, Inc
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms